engleski

Topoisomerase IIα in colorectal carcinoma: expression and prognostic role

Aim and background: Since very few data have been published, the aim of this study was to investigate the expression and prognostic role of topoisomerase IIa in patients with colorectal cancer (CRC). Patients and methods: The expression of topo IIa was evaluated immunohistochemically (IHC) on archival paraffin-embedded samples of CRC tissue from 146 patients, 59 (40.4%) females and 87 (59.6%) males, operated on in our hospital at Department of Surgery. Their median age was 65 years (range 35-87). There were 32 (22.1%) Dukes A, 46 (31.7%) Dukes B, 46 (31.7%) Dukes C tumors and 21(14.5%) tumors with distant metastasis. IHC was carried out by using the MoAb anti-human TOPO-IIa antibody (DAKO No K 0355). Immunoreactivity was scored semiquantitatively so that patients could be divided into the three groups according to the percentage of tumor cells staining topo IIa positive: group 1 (£ 10% ; n = 10 (7%)), group 2 (11-50% ; n = 85 (58%)) and group 3 (>50% ; n = 51 (35%)). Obtained IHC results were correlated with the following clinicopathological parameters: tumor stage (Dukes classification), tumor grade, vascular invasion and patients survival. All results are expressed as median (range). Results: The follow up period was 72 (0-95) months. A trend toward statistically significant worse survival was observed for the patient group 1 (30%) comparing to group 2 (57.6%) and group 3 (51.0%), but result was not statistically significant (30% vs 57.6%, p = 0.051 ; 30% vs 51%, p = 0.131). Toppo IIa expression was not found to be statistically different among patients arranged according to the Dukes tumor stage (Dukes A = 35% ; B = 35% ; C = 32.5% ; tumor stage with distant metastases = 40%). Also, there was no significant correlation between the topo IIa expression and tumor grade (g) (g 1 = 40%, g 2 = 35%, g 3 = 35%), vascular invasion (without = 35%, with = 40%) and lymph node affection (N0 = 35%, N+ = 40%). Conclusion: No significant correlation between the mentioned clinicopathologic parameters and the topo IIa was identified. The only exception were the patients’ survival data which showed worse survival in patients with lower expression of topo IIa, but without statistical significance. Due to relative rarity of this type of research, additional studied in larger cohort of patient are needed.

colorectal cancer; topoisomerase IIalpha

nije evidentirano